Preliminary program
(per 2026-09-03)
September 17, 2026 – TP53 and its mutations in myeloid malignancies
08.00 – 08:45 | Registration
08:45 – 09:00 | Welcome and Opening [Bjørn Tore Gjertsen, chair, NAMLG]
Session 1 – TP53 biology and epidemiology
[Chairs: Bjørn Tore Gjertsen, Marianne Severinsen]
09:00 – 09:40 | Jean-Christophe Bourdon, SKGJ CMYC Keynote Lecture – The tumour-suppressive activity encoded by the TP53 gene does not require the full-length p53 protein
09:40 – 10.00 | Christer Nilsson, Swedish AML Group: TP53 Epidemiology in AML
10:00 – 10:45 Coffee break
Session 2 – Diagnostic and therapeutic strategies: from bench to bed
[Chairs: Anne Louise Tølbøll Sørensen, Pia Ettala]
10:45 – 11:20 | Klas Wiman, SKGJ CMYC Keynote Lecture – Mutant p53 as a therapeutic target in cancer
11:20 – 11:35 | Amos Tuval: Enhancing APR-246 efficacy by synergistic drug combination in TP53-mutated AML
11:35 – 12.05 | Shah Mithun, TP53 mutated precursor and leukemic state
12:05 – 13:20 Lunch break
Session 3 – Contemporary and novel therapy of TP53 mutated myeloid malignancies
[Chairs: Sören Lehmann, Albin Österroos]
13:20 – 14:00 | Marina Konopleva, SKGJ CMYC Keynote Lecture, TP53 mutated myeloid malignancies: Montefiore approach
14:00 – 14:40 | Kim Theilgaard- Mønch, NAMLG Keynote Lecture, Overcoming chemotherapy resistance in TP53 defective AML through synthetic lethal combination therapy
14:40 – 15:30 | Coffee break
Session 4 – Experimental diagnostics and -omics
[Chairs: Håkon Reikvam]
15:30 – 15:50 | Anders Eivind Leren Myhre, TP53 Mutated Myeloid Neoplasms: Allo-HSCT at Any Cost?
15:50 – 16:25 | Hussain Abbas, Dissecting TP53 Mutated AML Through Multi-omic Integration
16:30 – 17:30 | Industry sponsored Session #1, Otsuka
New treatment options for fragile AML patients
[Chair: Bjørn Tore Gjertsen]
The session will be broadcasted on Teams.
16:30 – 16:35 | Ivar Haukeland, Brand Manager, Otsuka Pharma Scandinavia AB, Welcome
16:35 – 16:55 | Bjørn Tore Gjertsen, Early Nordic experience with new AML therapies
16:55 – 17:20 | Gail Roboz, The evolving AML treatment landscape
17:20 – 17:30 | Questions and discussion, moderated by Bjørn Tore Gjertsen
17:45 – 19:30 | Led by Jörg Cammenga and Håkon Reikvam – Poster-walk with microphone; 2 min per poster; Academic and Industry presenting their posters
20:00 – 23:00 | Conference Dinner @ Håkonshallen
September 18, 2026 – FLT3 Focus Day
08.00-09.00 | Industry Sponsored Session #2, Daiichi Sankyo
[Chair: Bjørn Tore Gjertsen]
08:00 – 08:30 | Pau Montesinos, Clinical development of FLT3/TKI inhibitors in wild type AML: fails and successes
08:30 – 09:00 | Mark J Levis, Management of FLT3-ITD AML
Session 6 – FLT3 biology and epidemiology
[Chairs: Jörg Cammenga, Anne Sophie von Krogh]
09:00 – 09.30 | Lars Rönnstrand, FLT3 and AML: History, Biology, and Signaling Pathways
09.30 – 10.00 | Gunnar Juliusson, FLT3-ITD in AML – data from the Swedish AML Registry
10:00 – 10:45 | Coffee break
Session 7 – Approaches for FLT3 targeted therapy
[Chairs: Anne Stidsholt Roug, Daniel Tuyet Kristensen]
10:45 | Announcement of Poster Prizes
10:45 – 11:15 | Jing Tang, Computational approaches for rationalizing drug combinations in AML
11:15 – 11:45 | Ton Falques, Clonal evolution under therapy in KMT2A-rearranged leukemia in a FLT3N676K mouse model
11.45-12.05 | Yngvar Fløysand, What is the role of FLT3 TKI maintenance in FLT3+ AML?
12.05-12.25 | Marc Raaijmakers, Upfront FLT3-inhibition in AML patients eligible for intensive chemotherapy
12:25 – 13:30 | Lunch break
Session 8 – FLT3 and the devil in the details
[Chairs: Bjørn Tore Gjertsen, Sören Lehmann]
13:30 – 13.50 | Francesca Sacco, How the FLT3-ITD insertion site shapes therapy resistance: a systems biology approach
13:50 – 14.30 | Pau Montesinos, Why and how should FLT3 inhibitors work in FLT3wt AML?
14:30 – 14.50 | Mark J Levis, Using MRD to manage FLT3-mutated AML
14:50 – 15:00 | Bjørn Tore Gjertsen, Closing remarks
